Ninth Circuit Opens Door to FCA Liability for 340B Overcharges — New Legal Pathway for FQHCs
The Ninth Circuit unanimously reversed a dismissal in United States ex rel. Adventist Health System v. AbbVie, ruling that qui tam False Claims Act suits can proceed against pharmaceutical manufacturers that allegedly overcharge 340B covered entities above the statutory ceiling price.
This creates a new private enforcement mechanism — previously only HRSA could enforce 340B ceiling price compliance. FQHCs can now pursue treble damages against manufacturers overcharging on 340B drugs.
Primary source
Sidley Austin LLPFQHC Talent. (2026, March 17). Ninth Circuit Opens Door to FCA Liability for 340B Overcharges — New Legal Pathway for FQHCs. Primary source: Sidley Austin LLP. Retrieved June 12, 2026, from https://www.fqhctalent.com/intel/ninth-circuit-fca-340b-overcharges-march-2026
More in Risk & Compliance
Jul 5
Section 1557 Language Access Annual Notice Year 1 Anniversary — July 5, 2026 Compliance Window
Jun 9
FTCA CY2027 redeeming applications due June 26 — miss it and your FQHC has a malpractice-coverage gap
Jun 1
Two Compliance Signals for FQHCs: HRSA's FY2026 340B Manufacturer-Audit Results Go Live, and OCR's Ransomware Settlements Preview a Tougher HIPAA Security Rule
Jun 1
Eli Lilly Gives ~50 Covered Entities Five Days to Hand Over 340B Claims Data — or Lose Their Discounts